Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with sunitinib malate may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving sunitinib malate together with combination chemotherapy works as front-line therapy in treating patients with metastatic rectal cancer that cannot be removed by surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Colorectal Cancer Metastatic Cancer |
Drug: FOLFIRI regimen Drug: fluorouracil Drug: irinotecan hydrochloride Drug: leucovorin calcium Drug: sunitinib malate Other: laboratory biomarker analysis Other: pharmacogenomic studies Other: pharmacological study |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Front-line Combination Therapy of Sunitinib Malate Plus Chemotherapy With Leucovorin/5-Fluorouracil and Irinotecan (FOLFIRI) for Rectal Cancer Patients With Synchronous Non-Resectable Metastases: A Phase II Non Controlled Study. (SUREMETS) |
- Response rate at 3 months as assessed by RECIST criteria [ Designated as safety issue: No ]
- Rate of complete response after resection [ Designated as safety issue: No ]
- Rate of R0 resection of metastases [ Designated as safety issue: No ]
- Rate of local failure [ Designated as safety issue: No ]
- Rate of local complications [ Designated as safety issue: No ]
- Metastatic progression-free survival [ Designated as safety issue: No ]
- Local progression-free survival [ Designated as safety issue: No ]
- Disease-free survival [ Designated as safety issue: No ]
- Symptom-free survival [ Designated as safety issue: No ]
- Overall survival [ Designated as safety issue: No ]
- Quality of life, specifically fatigue and global health score (EORTC QLQ-C30) [ Designated as safety issue: No ]
- Time to deterioration of the final score for overall health and fatigue [ Designated as safety issue: No ]
- Tolerance and incidence of side effects as assessed by NCI CTCAE v2 [ Designated as safety issue: Yes ]
- Translational research including pharmacodynamic studies of plasma and rectal tumor biopsies and histological and molecular studies [ Designated as safety issue: No ]
| Estimated Enrollment: | 70 |
| Study Start Date: | April 2009 |
OBJECTIVES:
Primary
- Evaluation of the efficacy of front-line treatment with sunitinib malate and FOLFIRI chemotherapy at 3 months in patients with rectal cancer and synchronous metastases deemed unresectable in a multidisciplinary consultation.
Secondary
- Evaluate the rate of resection of secondary metastases and rectal cancer, rate of R0 resection of metastases and rectal cancer, and the rate of complete response after resection.
- Evaluate the rate of local failure (progression of rectal cancer).
- Evaluate the rate of local complications.
- Evaluate disease-free survival.
- Evaluate progression-free survival, metastatic progression-free survival, and local progression-free survival.
- Evaluate symptom-free survival.
- Evaluate overall survival.
- Evaluate quality of life, specifically fatigue and global health score (EORTC QLQ-C30).
- Evaluate the tolerance to treatment.
- Conduct translational research, in particular, pharmacokinetic studies of plasma and rectal tumor biopsies, and histological and molecular studies.
OUTLINE: Patients receive simplified FOLFIRI chemotherapy comprising irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on days 1, 15, and 29. Patients also receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
Patients may undergo surgical resection and/or local radiotherapy if the tumor regresses. After resection or radiotherapy, patients may undergo up to 4 more courses of study treatment.
Biopsies of the tumor and healthy mucosa are collected for translational research at baseline. Blood samples are collected for pharmacodynamic and pharmacogenetic studies at baseline and at week 6. Patients also complete a quality-of-life questionnaire (EORTC QLQ-C30) at baseline and periodically thereafter.
After completion of study therapy, patients are followed up every 12 weeks.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed adenocarcinoma of the rectum
- Lower pole of the tumor < 12 cm from the anal margin
Synchronous metastases of the liver and/or lung
- Unresectable or resectability uncertain according to the decision of a local multidisciplinary consultation
- Lesions measurable in 1 dimension by RECIST criteria (metastases and primary rectal cancer)
- No rectal obstruction requiring surgery or the emergency fitting of a prosthesis
- No CNS metastases
PATIENT CHARACTERISTICS:
- WHO performance status 0-2
- ANC ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Creatinine clearance ≥ 60 mL/min
- Hemoglobin ≥ 10 g/dL (transfusions allowed)
- FEV ≥ 50%
- QT interval ≤ 450 ms (in men) or ≤ 470 ms (in women)
- Total bilirubin ≤ 1.5 times upper limit of normal
- Serum albumin ≥ 25 g/L
- Not pregnant or nursing
- Fertile patients must use effective contraception
No history of another cancer except for nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix
- History of other cancers allowed provided the patient has been disease-free > 3 years
None of the following:
- Congestive heart failure or coronary heart disease
- Myocardial infarction within the past year
- Uncontrolled hypertension (systolic BP > 160 mm Hg or diastolic BP > 100 mm Hg) despite optimal medical management
- No active severe rectal bleeding
- No liver failure
- No known Gilbert syndrome
- No severe uncontrolled infection
- No chronic diarrhea, malabsorption syndrome, or intestinal obstruction/subocclusion
- No severe uncontrolled pain (visual analogue scale 5/10) with morphine treatment
- No other medical, psychological, or social condition that, in the investigator's opinion, could affect the patient's compliance with study treatment
- No hypersensitivity to any component of study treatment
PRIOR CONCURRENT THERAPY:
- See Patient Characteristics
- No prior radiotherapy to the pelvis
- More than 4 weeks since prior experimental therapy
- More than 7 days since prior CYP3A4 inhibitor before the administration of sunitinib malate
- More than 12 days since prior CYP3A4 inducer
- No concurrent participation in another clinical study
- No other concurrent anticancer therapy
Contacts and Locations| France | |
| Hopital Ambroise Pare | Recruiting |
| Boulogne Billancourt, France, 92100 | |
| Contact: Philippe Rougier, MD 33-1-49-095-325 philippe.rougier@apr.aphp.fr | |
| Principal Investigator: | Philippe Rougier, MD | Hopital Ambroise Pare |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00936832 History of Changes |
| Other Study ID Numbers: | CDR0000637832, FFCD-0801, EUDRACT-2008-005959-19, EU-20918 |
| Study First Received: | July 8, 2009 |
| Last Updated: | July 23, 2009 |
| Health Authority: | Unspecified |
Keywords provided by National Cancer Institute (NCI):
|
stage IV rectal cancer adenocarcinoma of the rectum liver metastases lung metastases |
Additional relevant MeSH terms:
|
Rectal Neoplasms Colorectal Neoplasms Neoplasm Metastasis Neoplasms Neoplasms, Second Primary Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases Colonic Diseases Neoplastic Processes |
Pathologic Processes Fluorouracil Irinotecan Sunitinib Camptothecin Leucovorin Levoleucovorin Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antimetabolites, Antineoplastic Antineoplastic Agents Therapeutic Uses Immunosuppressive Agents Immunologic Factors |
ClinicalTrials.gov processed this record on May 21, 2013